A Comparative Effectiveness Trial of Extended-release Naltrexone and Extended-release Buprenorphine (Brixadi) with Individuals Leaving Jail (034)

Active

Study Information

The Friends Research Institute JCOIN Research Center is conducting a comparative effectiveness trial of extended-release naltrexone (XR-NTX) versus a new extended-release formulation of buprenorphine (Brixadi, XR-B) to treat opioid use disorder (OUD) among justice-involved individuals in ten Maryland county jails.

Participants will be randomly assigned to receive either XR-NTX or XR-B prior to release from jail, followed by six monthly injections while in the community. The goal of the study is to evaluate the effectiveness of the two medications, measure medication adherence, and gather data to inform broader scale-up of medications for opioid use disorder (MOUD) in jails and in the community.


Study Settings: Jails/Prisons, Treatment/Healthcare Settings

Study Location: Maryland

Study Team

PI/MPI:

Michael Gordon, DPA
Friends Research Institute

Shannon Gwin Mitchell, PhD
Friends Research Institute


Health Agency Partner:

Daniel Jarvis
Behavioral Health System Baltimore, Inc.


Justice Agency Partner:

Martha Danner
Frostburg State University

Logo of Friends Research Institute (FRI)

Study Aims

• Determine the effectiveness of XR-B versus XR-NTX

• Identify factors related to acceptability/feasibility of providing MOUD in jails

• Measure outcomes including substance use, overdose, and recidivism

• Identify best practices to inform expanded use of extended-release MOUD in jails and in the community

• Calculate the cost of implementing these medications in justice settings

Research Type

Clinical Trial, MOUD Comparative Effectiveness